Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1-Reference-Cited by-同舟云学术

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

Published:2020-03-03 Issue:3 Volume:108 Page:566-574
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Vugmeyster Yulia¹,Wilkins Justin²,Koenig Andre³,El Bawab Samer³,Dussault Isabelle¹,Ojalvo Laureen S.¹,De Banerjee Samrita¹,Klopp‐Schulze Lena³,Khandelwal Akash³

Affiliation:

1. EMD Serono Research & Development Institute, Inc.; a business of Merck KGaA Darmstadt Germany

2. Occams Coöperatie U.A. Amstelveen The Netherlands

3. Merck KGaA Darmstadt Germany

Funder

Merck KGaA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1776

Reference27 articles.

1. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

2. Immuno-Oncology: Emerging Targets and Combination Therapies

3. The blockade of immune checkpoints in cancer immunotherapy

4. Mechanisms of Immune Evasion by Tumors

5. Comprehensive analysis of the clinical immuno-oncology landscape

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure;JAMA Oncology;2024-07-25

2. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer;Journal for ImmunoTherapy of Cancer;2024-03

3. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer;Clinical Cancer Research;2024-01-02

4. Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials;CPT: Pharmacometrics & Systems Pharmacology;2023-12-13

5. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial;Journal of Thoracic Oncology;2023-12